Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

A user on Finasteride for over a year is asking if taking Glycine 1000 mg at night along with morning collagen peptides will increase DHT and cause hair loss. They are concerned about the potential impact on their hair loss treatment.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

A 35-year-old male is experiencing diffuse thinning and is using finasteride, topical minoxidil, and dutasteride. He is considering a hair transplant but is advised to wait and continue with medications for now.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

RU58841 is praised for its fast-acting effects on hair regrowth, with the user also using finasteride, minoxidil, dutasteride, and GHKcu. Some users report side effects like chest pain, while others see positive results, but it's unclear which treatment is most effective due to multiple compounds being used simultaneously.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 20-year-old male with diffuse androgenetic alopecia tried homeopathy for hair regrowth but saw limited results due to inconsistency and is considering switching to minoxidil and finasteride. Despite some baby hair growth, hair fall hasn't stopped, and he believes more time and consistency might be needed.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

Pelage plans to release PP405 trial results at a medical meeting in early 2026, possibly during the AAD conference in March. There is speculation about whether new hair loss treatments or GTA 6 will be released first.

The user has tried various treatments for hair loss, including finasteride, dutasteride, and oral minoxidil, but is considering a hair transplant due to insufficient progress. Some users suggest that the treatments have at least stabilized hair loss, and recommend consulting clinics for a potential hair transplant while continuing medication.

Vitamin D3 deficiency and gut health, particularly H. pylori overgrowth, can impact hair growth and overall health. Treatments like Minoxidil and finasteride may be ineffective if these issues are not addressed.

A user shared their experience with a second hair transplant by Dr. Gokhan Gur, focusing on the midscalp and crown with 1849 grafts. Their current treatment includes dutasteride, finasteride, oral and topical minoxidil, and Nizoral shampoo.

The user is concerned about having a straight, low hairline after a hair transplant and is unable to take finasteride due to high estrogen and prolactin levels. They have used minoxidil with limited success and are considering further transplants to lower the hairline, while others suggest the risks of using up donor hair too quickly.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The conversation discusses the availability and legitimacy of a hair loss treatment called PP405-3HP. Users express skepticism about its release and reference patent information.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A user underwent a 3750 graft hair transplant in Turkey, initially promised 4500 grafts, and is satisfied with the results despite some concerns about donor site size and crown coverage. The user has been on medications like finasteride and minoxidil for about four months and may consider a second transplant in the future.

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.